Atlas Trials

Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Clinical trial NCT06823960 · RECRUITING

Trial details

NCT number
NCT06823960
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Status
RECRUITING
Study type
OBSERVATIONAL
Marginal Zone Lymphoma(MZL)
Start date
2024-12-09
Primary completion
2025-06-01
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.